White Papers & Briefs List

This paper discusses why we have taken so long to adopt Metabolic Archetypes™ and thier benefit.

This Position Paper looks at two common paths people take on their weight loss journey—one based on conventional advice, the other based on addressing the root cause: insulin resistance.

This white paper unpacks the biological reality behind body composition, outlines the most powerful interventions, and introduces a return-on-investment (ROI) framework to prioritize actions based on impact and common metabolic dysfunctions.

This Insight Paper describes the rate of uptake of fats to adipose tissue (body fat) with and without the influence of insulin. This is very relavant for those who ae insulin resistant with predominantly high insulin and applicable to the make-up of meals in terms of fats and carbohydrates.

This document outlines the 7 stages of Insulin Resistance Progression. It provides Triglyceride-Glucose Index reading reference estimates for each stage. Changes, physiological symptoms and key implications are provided for each stage. This is a key document for making clear that several chronic diseases are not just arbetray chance occurances, but raather a progression on one unattended physiological condition.

There remains a profound gap between intending to act and actually taking action. This paper outlines a practical, systems-based model for understanding and overcoming that gap.

Why Reversing Cardiovascular Disease Requires More Than Just Lowering Cholesterol. It is not simply the presence of cholesterol in the bloodstream that causes arterial damage, but rather the interaction of small dense LDL particles, oxidative stress, chronic inflammation, hypertension, and endothelial glycocalyx degradation.

This white paper introduces the concept of Metabolic Archetypes™ as a modern, scientifically plausible alternative grounded in genetics, metabolic biomarkers, and physiological indicators.

Discussion covers a more complete and effective approach to health and fitness changes.

Behavior change isn’t about “forming habits.”

It’s about intentionally integrating biologically meaningful tasks into environments that support execution, reduce resistance, and enable consistency over time.

Discussed is its purpose, how it works, relevance to GLP-1 post use, and relationship to bio-impedance (BIA) measurement.

Discusses loss of "Lean Body Mass" with GLP-1 medications or hypocaloric diets and the necessary countermeasures to avoid it.